Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
DICE Therapeutics Inc (DICE) Stock Price & Overview
NASDAQ:DICE • US23345J1043
Current stock price
47.55 USD
+0.03 (+0.06%)
At close:
47.59 USD
+0.04 (+0.08%)
After Hours:
The current stock price of DICE is 47.55 USD. Today DICE is up by 0.06%. In the past month the price increased by 1.67%. In the past year, price increased by 136.1%.
DICE Key Statistics
52-Week Range15.08 - 47.9
Current DICE stock price positioned within its 52-week range.
1-Month Range46.56 - 47.9
Current DICE stock price positioned within its 1-month range.
- Market Cap
- 2.272B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.18
- Dividend Yield
- N/A
DICE Stock Performance
Today
+0.06%
1 Week
+0.72%
1 Month
+1.67%
3 Months
+32.90%
Longer-term
6 Months +69.46%
1 Year +136.10%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
DICE Stock Chart
DICE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DICE. When comparing the yearly performance of all stocks, DICE is one of the better performing stocks in the market, outperforming 98.59% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
DICE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DICE. DICE has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DICE Earnings
Next Earnings DateN/A
Last Earnings DateAug 10, 2023
PeriodQ1 / 2023
EPS Reported-$0.54
Revenue Reported
EPS Surprise 9.57%
Revenue Surprise %
DICE Forecast & Estimates
14 analysts have analysed DICE and the average price target is 50.36 USD. This implies a price increase of 5.91% is expected in the next year compared to the current price of 47.55.
Analysts
Analysts52.86
Price Target50.36 (5.91%)
EPS Next Y-22.45%
Revenue Next YearN/A
DICE Financial Highlights
Over the last trailing twelve months DICE reported a non-GAAP Earnings per Share(EPS) of -2.18. The EPS decreased by -20.98% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-90.94M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-8%
Sales Q2Q%N/A
EPS 1Y (TTM)-20.98%
Revenue 1Y (TTM)-100%
DICE Ownership
Ownership
Inst Owners0.04%
Shares47.79M
Float41.85M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
DICE Industry Overview
DICE operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
35%
Outperformed 35% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 3.7%
- New Lows
- 4.4%
- Average ROE
- 50.3%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.4%
- Average P/E
- 26.1
- Average Fwd P/E
- 20.5
- Average Debt/Equity
- 1.2
DICE Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.69 | 804.24B | ||
| JNJ | JOHNSON & JOHNSON | 18.15 | 547.597B | ||
| MRK | MERCK & CO. INC. | 21.75 | 274.033B | ||
| PFE | PFIZER INC | 8.94 | 149.376B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.47 | 117.584B | ||
| ZTS | ZOETIS INC | 16.14 | 47.868B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.71 | 28.553B | ||
| VTRS | VIATRIS INC | 6.05 | 17.431B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.05 | 10.887B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.409B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.108B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.796B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.15 | 4.956B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DICE
Company Profile
DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing oral therapeutics against well-validated targets in immunology. The firm's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The firm's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The firm is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
Company Info
IPO: 2021-09-15
DICE Therapeutics Inc
400 East Jamie Court, Suite 300
South San Francisco CALIFORNIA US
CEO: J. Kevin Judice
Employees: 81
Phone: 16505661402.0
DICE Therapeutics Inc / DICE FAQ
Can you describe the business of DICE Therapeutics Inc?
DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing oral therapeutics against well-validated targets in immunology. The firm's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The firm's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The firm is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
What is the current price of DICE stock?
The current stock price of DICE is 47.55 USD. The price increased by 0.06% in the last trading session.
Does DICE Therapeutics Inc pay dividends?
DICE does not pay a dividend.
What is the ChartMill technical and fundamental rating of DICE stock?
DICE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists DICE stock?
DICE stock is listed on the Nasdaq exchange.
Can you provide the market cap for DICE Therapeutics Inc?
DICE Therapeutics Inc (DICE) has a market capitalization of 2.27B USD. This makes DICE a Mid Cap stock.